MX2018002038A - Formulaciones clinicas. - Google Patents

Formulaciones clinicas.

Info

Publication number
MX2018002038A
MX2018002038A MX2018002038A MX2018002038A MX2018002038A MX 2018002038 A MX2018002038 A MX 2018002038A MX 2018002038 A MX2018002038 A MX 2018002038A MX 2018002038 A MX2018002038 A MX 2018002038A MX 2018002038 A MX2018002038 A MX 2018002038A
Authority
MX
Mexico
Prior art keywords
clinical
tissue
preparations
cell
media
Prior art date
Application number
MX2018002038A
Other languages
English (en)
Inventor
Gay Roger
RATLIFF Judson
E Southwick Romma
Original Assignee
Astellas Inst For Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Inst For Regenerative Medicine filed Critical Astellas Inst For Regenerative Medicine
Publication of MX2018002038A publication Critical patent/MX2018002038A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure

Abstract

Algunos aspectos de esta descripción proporcionan medios clí­nicos que soportan la viabilidad, eficiencia de re-distribución, y capacidad de repoblación de cólulas y tejidos durante el almacenado por hasta 48 horas o más tiempo. Los medios clí­nicos proporcionados en la presente también son útiles para irrigación clí­nica. Tambión se proporcionan en preparaciones celulares o de tejido que comprenden una población celular o tejido y un medio clí­nico como se proporciona en la presente, que son métodos para generar tales preparaciones. Tambión se describen métodos para usar los medios clí­nicos y preparaciones de cólulas y tejidos proporcionados en la presente, por ejemplo, para administrar una cantidad efectiva de cólulas o tejido a un sujeto que necesite del mismo.
MX2018002038A 2015-08-18 2016-08-18 Formulaciones clinicas. MX2018002038A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206821P 2015-08-18 2015-08-18
PCT/US2016/047545 WO2017031312A1 (en) 2015-08-18 2016-08-18 Clinical formulations

Publications (1)

Publication Number Publication Date
MX2018002038A true MX2018002038A (es) 2018-07-06

Family

ID=56843032

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018002038A MX2018002038A (es) 2015-08-18 2016-08-18 Formulaciones clinicas.
MX2022010363A MX2022010363A (es) 2015-08-18 2018-02-16 Formulaciones clinicas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022010363A MX2022010363A (es) 2015-08-18 2018-02-16 Formulaciones clinicas.

Country Status (16)

Country Link
US (2) US11013808B2 (es)
EP (1) EP3334415A1 (es)
JP (2) JP7043392B2 (es)
KR (3) KR102411018B1 (es)
CN (1) CN108697641A (es)
AU (2) AU2016308818B2 (es)
BR (1) BR112018003031B1 (es)
CA (1) CA2995977A1 (es)
EA (2) EA202190722A1 (es)
HK (1) HK1256839A1 (es)
IL (3) IL299326A (es)
MX (2) MX2018002038A (es)
PH (1) PH12018500371A1 (es)
SG (1) SG10201913250SA (es)
TW (2) TWI772270B (es)
WO (1) WO2017031312A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
JP6882981B2 (ja) 2014-12-30 2021-06-02 セル キュア ニューロサイエンシズ リミテッド Ｒｐｅ細胞集団およびそれを作製する方法
WO2016154357A1 (en) 2015-03-23 2016-09-29 Ocata Therapeutics, Inc. Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
EP3334415A1 (en) 2015-08-18 2018-06-20 Astellas Institute for Regenerative Medicine Clinical formulations
EP3479832A4 (en) * 2016-06-30 2019-12-18 Healios K.K. TRANSPLANTATION ENVIRONMENT
BR112020013238A2 (pt) * 2017-12-29 2020-12-01 Cell Cure Neurosciences Ltd. composição e método para formular células do epitélio pigmentar da retina bem como uso da dita composição para tratar uma condição retiniana
CA3151637A1 (en) 2019-08-28 2021-03-04 Astellas Institute For Regenerative Medicine Methods of treating vascular diseases
TW202122573A (zh) 2019-08-28 2021-06-16 安斯泰來再生醫藥協會 治療血管疾病之組成物及方法
US20230072771A1 (en) 2019-10-30 2023-03-09 Astellas Institute For Regenerative Medicine Methods for producing retinal pigment epithelium cells
JP7018527B1 (ja) 2020-12-16 2022-02-10 アニコム先進医療研究所株式会社 細胞の保存方法および細胞懸濁液
CA3225810A1 (en) * 2021-07-15 2023-01-19 Joseph Piccirilli Preservative composition for nucleic acids and biological samples and methods of use
WO2023176906A1 (ja) * 2022-03-16 2023-09-21 住友ファーマ株式会社 移植用媒体
WO2024019962A1 (en) 2022-07-18 2024-01-25 Astellas Institute For Regenerative Medicine Methods of treating brain injury
WO2024044134A1 (en) 2022-08-23 2024-02-29 Astellas Institute For Regenerative Medicine Photoreceptor rescue cell (prc) compositions and methods for treatment of ocular disorders

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654266A (en) * 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
EP0562188B1 (en) * 1992-03-27 1998-09-30 Chung-Ho Chen Composition for tissues to sustain viability and biological functions in surgery and storage
WO1994028950A1 (en) 1993-06-04 1994-12-22 Biotime, Inc. Plasma-like solution
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
EP1008341B1 (en) * 1997-08-22 2004-06-30 Shimizu Pharmaceutical Co., Ltd. Glucose-containing preparation
GB2336109A (en) 1998-04-07 1999-10-13 Univ Bristol Ophthalmic Irrigating Solution
ATE312614T1 (de) 2000-01-11 2005-12-15 Ophtecs Corp Perfusionslösung zusammensetzungen für ophthalmische verfahren
US7084157B2 (en) * 2002-05-17 2006-08-01 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
US20190282622A1 (en) 2004-01-23 2019-09-19 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
SG10201606441SA (en) 2004-01-23 2016-09-29 Astellas Inst For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP2377925A1 (en) 2006-04-14 2011-10-19 Advanced Cell Technology, Inc. Hemangio-colony forming cells
KR20090043559A (ko) * 2006-08-15 2009-05-06 에이전시 포 사이언스, 테크놀로지 앤드 리서치 중간엽 줄기세포 조절배지
AU2008312007A1 (en) 2007-10-12 2009-04-23 Advanced Cell Technology, Inc. Improved methods of producing RPE cells and compositions of RPE cells
AU2009244236B2 (en) 2008-05-06 2015-03-12 Astellas Institute For Regenerative Medicine Methods for producing enucleated erythroid cells derived from pluripotent stem cells
MX2010012088A (es) 2008-05-06 2011-07-28 Advanced Cell Tech Inc Celulas que forman colonias de hemangiomas y celulas de hemangioma sin injertar.
US10485829B2 (en) 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
CN102822332A (zh) 2009-12-04 2012-12-12 干细胞及再生医学国际股份有限公司 从源于人胚胎干细胞的成血管细胞产生自然杀伤细胞和树突细胞的方法
KR20180086301A (ko) 2009-12-04 2018-07-30 스템 셀 앤드 리제너러티브 메디신 인터내셔날, 인크. 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성
CA2806127C (en) 2010-07-23 2021-12-21 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
DK2780022T3 (da) 2011-11-14 2019-07-15 Astellas Inst For Regenerative Medicine Farmaceutiske præparater af humane rpe-celler og anvendelser deraf
DK2785359T3 (en) 2011-11-30 2018-10-29 Astellas Inst For Regenerative Medicine MESENKYMAL STROMACELLES AND APPLICATIONS RELATED
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
RS58526B1 (sr) 2011-12-06 2019-04-30 Astellas Inst For Regenerative Medicine Postupak usmerene diferencijacije koja proizvodi kornealne endotelijalne ćelije
CN103783031B (zh) * 2012-10-29 2015-11-18 四川新生命干细胞科技股份有限公司 一种细胞保存液
AU2013201546B2 (en) 2012-12-18 2014-10-23 Gambro Lundia Ab Dialysis composition
CA2896053A1 (en) 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
CA2906815A1 (en) 2013-03-15 2014-09-18 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160175362A1 (en) 2014-03-14 2016-06-23 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160175361A1 (en) 2014-03-14 2016-06-23 Advanced Cell Technology, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
SG10201901559SA (en) 2014-09-05 2019-03-28 Astellas Inst For Regenerative Medicine Retinal ganglion cells and progenitors thereof
WO2016154357A1 (en) 2015-03-23 2016-09-29 Ocata Therapeutics, Inc. Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
EP3334415A1 (en) * 2015-08-18 2018-06-20 Astellas Institute for Regenerative Medicine Clinical formulations
TW202122573A (zh) 2019-08-28 2021-06-16 安斯泰來再生醫藥協會 治療血管疾病之組成物及方法
CA3151637A1 (en) 2019-08-28 2021-03-04 Astellas Institute For Regenerative Medicine Methods of treating vascular diseases
US20230072771A1 (en) 2019-10-30 2023-03-09 Astellas Institute For Regenerative Medicine Methods for producing retinal pigment epithelium cells

Also Published As

Publication number Publication date
BR112018003031A2 (pt) 2018-09-18
NZ740608A (en) 2023-09-29
CN108697641A (zh) 2018-10-23
MX2022010363A (es) 2022-09-21
JP2022040140A (ja) 2022-03-10
EA201890516A1 (ru) 2018-09-28
KR20220090583A (ko) 2022-06-29
US20190030168A1 (en) 2019-01-31
JP2018523682A (ja) 2018-08-23
IL257551B (en) 2022-04-01
IL291163B1 (en) 2023-01-01
EA037915B1 (ru) 2021-06-07
SG10201913250SA (en) 2020-03-30
KR20180048722A (ko) 2018-05-10
US11013808B2 (en) 2021-05-25
AU2016308818A1 (en) 2018-04-05
US20190358330A9 (en) 2019-11-28
TWI772270B (zh) 2022-08-01
KR102651291B1 (ko) 2024-03-26
IL257551A (en) 2018-04-30
JP7043392B2 (ja) 2022-03-29
TWI833293B (zh) 2024-02-21
KR20230058544A (ko) 2023-05-03
EP3334415A1 (en) 2018-06-20
US20210275673A1 (en) 2021-09-09
TW201717912A (zh) 2017-06-01
AU2022206757A1 (en) 2022-08-18
PH12018500371A1 (en) 2018-08-29
IL299326A (en) 2023-02-01
KR102411018B1 (ko) 2022-06-20
JP7449915B2 (ja) 2024-03-14
WO2017031312A1 (en) 2017-02-23
HK1256839A1 (zh) 2019-10-04
CA2995977A1 (en) 2017-02-23
IL291163B2 (en) 2023-05-01
EA202190722A1 (ru) 2021-10-29
TW202245816A (zh) 2022-12-01
US11957754B2 (en) 2024-04-16
AU2016308818B2 (en) 2022-04-21
IL291163A (en) 2022-05-01
BR112018003031B1 (pt) 2023-12-26

Similar Documents

Publication Publication Date Title
PH12018500371A1 (en) Clinical formulations
MX2017004890A (es) Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
DOP2020000071A (es) Proteínas trispecificas y métodos de uso
MX2015012729A (es) Celulas discogenicas aisladas, metodos de uso y metodos de preparacion de las mismas a partir de tejido de mamiferos.
WO2017106537A3 (en) Targeted disruption of the mhc cell receptor
WO2014028493A3 (en) Exosomes and micro-ribonucleic acids for tissue regeneration
MX2020005503A (es) Metodos para activar, modificar y expandir linfocitos t gamma delta para el tratamiento del cancer y de neoplasias malignas relacionadas.
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
WO2016201047A8 (en) Crispr/cas-related methods and compositions for improving transplantation
SG10201804330YA (en) Engineered high-affinity human t cell receptors
MX2020003413A (es) Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia.
WO2016027099A3 (en) Resetting pluripotent stem cells
MY192561A (en) Taurine supplemented cell culture medium and methods of use
MX2017002900A (es) Terapia genica de globina para el tratamiento de hemoglobinopatias.
PH12021550846A1 (en) Compositions and methods for expressing factor ix
MY155137A (en) Compounds that expand hematopoietic stem cells
CY1119382T1 (el) Φυσικα βλαστοκυτταρα γελης toy wharton και καθαρισμος αυτων
WO2012048093A3 (en) Enhanced msc preparations
GB2562396A (en) Devices for simulating a function of a liver tissue and methods of use and manufacturing thereof
WO2014053418A3 (en) Method for obtaining mesenchymal stem cells and use thereof
WO2012027514A3 (en) Compositions and methods for cardiac therapy
MX2019008872A (es) Prevencion y tratamiento de da?o o enfermedad osea y cartilago.
IN2015DN02729A (es)
CR20150310A (es) Solución para preservar conductos vasculares
PH12014501309A1 (en) Mammalian fetal pulmonary cells and therapeutic use of same